Clinical Trials
9 trialsNCT02359565 2026-05-13
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05838768 2026-03-24
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
Novartis
Phase 1 Active not recruiting
NCT03607890 2026-03-16
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT04104893 2026-02-27
CHOMP
VA Office of Research and Development
Phase 2 Active not recruiting
NCT03767348 2026-02-13
IGNYTE
Replimune, Inc.
Phase 2 Active not recruiting
NCT06710847 2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT05118724 2025-06-15
ANTONIO
AIO-Studien-gGmbH
Phase 2 Active not recruiting
NCT02983578 2025-05-06
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting